Market revenue in 2023 | USD 213.9 million |
Market revenue in 2030 | USD 326.5 million |
Growth rate | 6.2% (CAGR from 2023 to 2030) |
Largest segment | Transvenous implantable cardioverter-defibrillators |
Fastest growing segment | Subcutaneous Implantable Cardioverter Defibrillators |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Transvenous Implantable Cardioverter-Defibrillators, Subcutaneous Implantable Cardioverter Defibrillators |
Key market players worldwide | Abbott Laboratories, Medtronic PLC, BIOTRONIK, Boston Scientific Corp, MicroPort Scientific Corp, LivaNova PLC |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to implantable cardioverter defibrillators market will help companies and investors design strategic landscapes.
Transvenous implantable cardioverter-defibrillators was the largest segment with a revenue share of 89.43% in 2023. Horizon Databook has segmented the Canada implantable cardioverter defibrillators market based on transvenous implantable cardioverter-defibrillators, subcutaneous implantable cardioverter defibrillators covering the revenue growth of each sub-segment from 2018 to 2030.
According to Canada's Heart and Stroke Foundation (HSF), an estimated 35,000 residents experience SCA annually. Furthermore, an estimated 750,000 people in the country are living with heart failure. Moreover, if an individual has experienced a previous cardiac arrest, he/she is at high risk of recurrent episodes.
An ICD may be recommended to monitor the heart rhythm and deliver therapy when needed to prevent sudden cardiac death. Moreover, as per an article published by Elsevier in November 2020, it was estimated that nearly 120,000 patients in Canada are living with a Cardiovascular Implantable Electronic Device (CIED), while approximately 7,000 ICDs & 25,000 pacemakers are implanted each year in the country.
In addition, the Canadian Cardiovascular Society and Canadian Heart Rhythm Society advocated actively using remote monitoring for follow-ups on CIED patients, even for devices with no active issues.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada implantable cardioverter defibrillators market , including forecasts for subscribers. This country databook contains high-level insights into Canada implantable cardioverter defibrillators market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account